References
1. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent
risk factor for stroke: the Framingham Study. Stroke 1991; 22: 983-988,
doi:10.1161/01.str.22.8.983.
2. Stewart S, Hart CL, Hole DJ, McMurray JJ. A population-based study of
the long-term risks associated with atrial fibrillation: 20-year
follow-up of the Renfrew/Paisley study. Am J Med 2002; 113: 359-364,
doi:10.1016/s0002-9343(02)01236-6.
3. Benjamin EJ, Wolf PA, D’Agostino RB, Silbershatz H, Kannel WB, Levy
D. Impact of atrial fibrillation on the risk of death: the Framingham
Heart Study. Circulation 1998; 98: 946-952,
doi:10.1161/01.cir.98.10.946.
4. Bunch TJ, Crandall BG, Weiss JP, May HT, Bair TL, Osborn JS, et al.
Patients treated with catheter ablation for atrial fibrillation have
long-term rates of death, stroke, and dementia similar to patients
without atrial fibrillation. J Cardiovasc Electrophysiol 2011; 22:
839-845, doi:10.1111/j.1540-8167.2011.02035.x.
5. Chang CH, Lin JW, Chiu FC, Caffrey JL, Wu LC, Lai MS. Effect of
radiofrequency catheter ablation for atrial fibrillation on morbidity
and mortality: a nationwide cohort study and propensity score analysis.
Circ Arrhythm Electrophysiol 2014; 7: 76-82,
doi:10.1161/circep.113.000597.
6. Friberg L, Tabrizi F, Englund A. Catheter ablation for atrial
fibrillation is associated with lower incidence of stroke and death:
data from Swedish health registries. Eur Heart J 2016; 37: 2478-2487,
doi:10.1093/eurheartj/ehw087.
7. Modin D, Claggett B, Gislason G, Hansen ML, Worck R, Johannessen A,
et al. Catheter ablation for atrial fibrillation is associated with
lower incidence of heart failure and death. Europace 2020; 22: 74-83,
doi:10.1093/europace/euz264.
8. Reynolds MR, Gunnarsson CL, Hunter TD, Ladapo JA, March JL, Zhang M,
et al. Health outcomes with catheter ablation or antiarrhythmic drug
therapy in atrial fibrillation: results of a propensity-matched
analysis. Circ Cardiovasc Qual Outcomes 2012; 5: 171-181,
doi:10.1161/circoutcomes.111.963108.
9. Okumura Y, Nagashima K, Arai M, Watanabe R, Yokoyama K, Matsumoto N,
et al. Current Status and Clinical Outcomes of Oral Anticoagulant
Discontinuation After Ablation for Atrial Fibrillation in Japan -
Findings From the AF Frontier Ablation Registry. Circ J 2019; 83:
2418-2427, doi:10.1253/circj.CJ-19-0602.
10. January CT, Wann LS, Alpert JS, Calkins H, Cigarroa JE, Cleveland
JC, Jr., et al. 2014 AHA/ACC/HRS guideline for the management of
patients with atrial fibrillation: a report of the American College of
Cardiology/American Heart Association Task Force on Practice Guidelines
and the Heart Rhythm Society. J Am Coll Cardiol 2014; 64: e1-76,
doi:10.1016/j.jacc.2014.03.022.
11. Calkins H, Hindricks G, Cappato R, Kim YH, Saad EB, Aguinaga L, et
al. 2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on
catheter and surgical ablation of atrial fibrillation. Europace 2018;
20: e1-e160, doi:10.1093/europace/eux274.
12. Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, et
al. 2016 ESC Guidelines for the management of atrial fibrillation
developed in collaboration with EACTS. Eur Heart J 2016; 37: 2893-2962,
doi:10.1093/eurheartj/ehw210.
13. Haïssaguerre M, Jaïs P, Shah DC, Takahashi A, Hocini M, Quiniou G,
et al. Spontaneous initiation of atrial fibrillation by ectopic beats
originating in the pulmonary veins. N Engl J Med 1998; 339: 659-666,
doi:10.1056/nejm199809033391003.
14. Kuck KH, Brugada J, Fürnkranz A, Metzner A, Ouyang F, Chun KR, et
al. Cryoballoon or Radiofrequency Ablation for Paroxysmal Atrial
Fibrillation. N Engl J Med 2016; 374: 2235-2245,
doi:10.1056/NEJMoa1602014.
15. Watson T, Shantsila E, Lip GY. Mechanisms of thrombogenesis in
atrial fibrillation: Virchow’s triad revisited. Lancet 2009; 373:
155-166, doi:10.1016/s0140-6736(09)60040-4.
16. Naito M, David D, Michelson EL, Schaffenburg M, Dreifus LS. The
hemodynamic consequences of cardiac arrhythmias: evaluation of the
relative roles of abnormal atrioventricular sequencing, irregularity of
ventricular rhythm and atrial fibrillation in a canine model. Am Heart J
1983; 106: 284-291, doi:10.1016/0002-8703(83)90194-1.
17. Gopinathannair R, Etheridge SP, Marchlinski FE, Spinale FG,
Lakkireddy D, Olshansky B. Arrhythmia-Induced Cardiomyopathies:
Mechanisms, Recognition, and Management. J Am Coll Cardiol 2015; 66:
1714-1728, doi:10.1016/j.jacc.2015.08.038.
18. Wyse DG, Waldo AL, DiMarco JP, Domanski MJ, Rosenberg Y, Schron EB,
et al. A comparison of rate control and rhythm control in patients with
atrial fibrillation. N Engl J Med 2002; 347: 1825-1833,
doi:10.1056/NEJMoa021328.
19. Corley SD, Epstein AE, DiMarco JP, Domanski MJ, Geller N, Greene HL,
et al. Relationships between sinus rhythm, treatment, and survival in
the Atrial Fibrillation Follow-Up Investigation of Rhythm Management
(AFFIRM) Study. Circulation 2004; 109: 1509-1513,
doi:10.1161/01.Cir.0000121736.16643.11.
20. Lin YJ, Chao TF, Tsao HM, Chang SL, Lo LW, Chiang CE, et al.
Successful catheter ablation reduces the risk of cardiovascular events
in atrial fibrillation patients with CHA2DS2-VASc risk score of 1 and
higher. Europace 2013; 15: 676-684, doi:10.1093/europace/eus336.
21. Hunter RJ, McCready J, Diab I, Page SP, Finlay M, Richmond L, et al.
Maintenance of sinus rhythm with an ablation strategy in patients with
atrial fibrillation is associated with a lower risk of stroke and death.
Heart 2012; 98: 48-53, doi:10.1136/heartjnl-2011-300720.
22. Ghanbari H, Başer K, Jongnarangsin K, Chugh A, Nallamothu BK,
Gillespie BW, et al. Mortality and cerebrovascular events after
radiofrequency catheter ablation of atrial fibrillation. Heart Rhythm
2014; 11: 1503-1511, doi:10.1016/j.hrthm.2014.05.003.
23. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh
A, et al. Dabigatran versus warfarin in patients with atrial
fibrillation. N Engl J Med 2009; 361: 1139-1151,
doi:10.1056/NEJMoa0905561.
24. Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M,
et al. Apixaban versus warfarin in patients with atrial fibrillation. N
Engl J Med 2011; 365: 981-992, doi:10.1056/NEJMoa1107039.
25. Yamashita T, Koretsune Y, Yang Y, Chen SA, Chung N, Shimada YJ, et
al. Edoxaban vs. Warfarin in East Asian Patients With Atrial
Fibrillation - An ENGAGE AF-TIMI 48 Subanalysis. Circ J 2016; 80:
860-869, doi:10.1253/circj.CJ-15-1082.
26. Chai-Adisaksopha C, Hillis C, Isayama T, Lim W, Iorio A, Crowther M.
Mortality outcomes in patients receiving direct oral anticoagulants: a
systematic review and meta-analysis of randomized controlled trials. J
Thromb Haemost 2015; 13: 2012-2020, doi:10.1111/jth.13139.
27. Abhayaratna WP, Seward JB, Appleton CP, Douglas PS, Oh JK, Tajik AJ,
et al. Left atrial size: physiologic determinants and clinical
applications. J Am Coll Cardiol 2006; 47: 2357-2363,
doi:10.1016/j.jacc.2006.02.048.
28. Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ.
Validation of clinical classification schemes for predicting stroke:
results from the National Registry of Atrial Fibrillation. JAMA 2001;
285: 2864-2870, doi:10.1001/jama.285.22.2864.
29. Risk factors for stroke and efficacy of antithrombotic therapy in
atrial fibrillation. Analysis of pooled data from five randomized
controlled trials. Arch Intern Med 1994; 154: 1449-1457.
30. Yamamoto K, Ikeda U, Furuhashi K, Irokawa M, Nakayama T, Shimada K.
The coagulation system is activated in idiopathic cardiomyopathy. J Am
Coll Cardiol 1995; 25: 1634-1640, doi:10.1016/0735-1097(95)00049-a.